Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q99967

UPID:
CITE2_HUMAN

ALTERNATIVE NAMES:
MSG-related protein 1; P35srj

ALTERNATIVE UPACC:
Q99967; O95426; Q5VTF4

BACKGROUND:
The protein Cbp/p300-interacting transactivator 2, with aliases MSG-related protein 1 and P35srj, acts as a crucial transcriptional coactivator. It positively regulates several key pathways, including TGF-beta signaling and estrogen-dependent transactivation, by facilitating the interaction between TFAP2 transcription factors and the p300/CBP coactivator complex. Additionally, it is essential for sex determination, embryogenesis, and adrenal cortex differentiation, highlighting its multifaceted role in development and disease.

THERAPEUTIC SIGNIFICANCE:
The association of Cbp/p300-interacting transactivator 2 with congenital heart defects, such as Ventricular septal defect 2 and Atrial septal defect 8, underscores its therapeutic potential. Targeting this protein could lead to innovative treatments for these and possibly other related cardiovascular conditions, emphasizing the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.